C
Chinook Therapeutics
Discovering and Developing Precision Medicines for Rare Kidney Diseases
About Chinook Therapeutics
Chinook Therapeutics, now a part of Novartis, is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of precision medicines for rare and severe chronic kidney diseases. The company operates in the biopharmaceutical market, focusing on innovative treatments for conditions that often lead to dialysis, transplantation, and significant healthcare costs. Chinook's business model revolves around advancing its drug candidates through clinical trials, obtaining regulatory approvals, and ultimately bringing these therapies to market. Revenue is generated through the commercialization of these precision medicines, targeting a niche but critical segment of the healthcare industry. The company serves patients suffering from chronic kidney diseases, healthcare providers, and the broader medical community. Chinook leverages its deep understanding of disease biology, novel translational platforms, and patient stratification tools to develop its therapies. The acquisition by Novartis is expected to bolster its research capabilities and accelerate the development of its drug pipeline.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2019
- Headquarters
- Seattle, United States
- Listing
- IPO 2020
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 28.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2020
- Capital deployed
- —
- Preferred round
- MERGER
Latest news
Press, funding announcements and product moves mentioning Chinook Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jun 2023 | $3.5B | — | Novartis | ↗ |
| POST IPO EQUITYOther financing | May 2022 | $105M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $6.1M | 0% | −$168M | -2741.5% |
| 2025 | $6.1M | 0% | −$168M | -2741.5% |
| 2024 | $6.1M | 0% | −$168M | -2741.5% |
| 2023 | $6.1M | 0% | −$168M | -2741.5% |
| 2022 | $6.1M | -88.1% | −$168M | -2741.5% |
| 2021 | $52M | +6142.4% | −$74M | -143.7% |
| 2020 | $827K | — | −$53M | -6442.7% |
Growth signals
Latest recorded traffic for Chinook Therapeutics is 420 monthly website visits, down 84.4% over the last three months. Chinook Therapeutics's team declined 81.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors12 additional known investors
Aduro BioTech
Ally Bridge Group
Avidity Partners
Citadel
EcoR1 Capital
Fidelity Investments
Janus Henderson Investors
Monashee Investment Management
Northleaf
Novartis
OrbiMed
Rock Springs Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chinook Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chinook Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.